Employees: 1,188
Size Beijing Beilu Pharmaceutical (300016.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $641M, the 3093rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.24 on 18 Nov 2026.
Performance Over six months the shares fell 19.0%, against -17.5% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 23.5% over the last twelve months (peer median +10.5%); the operating margin is 10.7% (peer median 9.2%).
Valuation It trades at 79.7× forward earnings against a peer median of 24.9× (3rd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.3 points below its cost of capital (6.9% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.39B | CN¥1.20B | CN¥977M | CN¥886M | CN¥760M |
| Revenue growth | — | +23% | +10% | +17% | — |
| Gross profit | CN¥642M | CN¥513M | CN¥428M | CN¥382M | CN¥385M |
| EBITDA | n/a | CN¥182M | CN¥150M | CN¥63.0M | CN¥94.6M |
| Net income | CN¥162M | CN¥92.7M | CN¥13.7M | -CN¥71.8M | CN¥11.3M |
| Free cash flow | CN¥102M | -CN¥42.0M | CN¥74.8M | -CN¥82.1M | CN¥37.4M |
| Capital expenditure | CN¥141M | CN¥219M | CN¥101M | CN¥145M | CN¥103M |
| Total debt | CN¥531M | CN¥607M | CN¥881M | CN¥822M | CN¥701M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300016.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.7% | -8.1% | 9th lowest of 20 |
| 6-month return | -19.0% | -17.5% | 9th lowest of 20 |
| Distance from 52-week high | -36.4% | -41.0% | 10th highest of 20 |
| Revenue growth (TTM) | +23.5% | +10.5% | 6th highest of 17 |
| Operating margin | 10.7% | 9.2% | 7th highest of 16 |
| Forward P/E | 79.7× | 24.9× | 3rd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 9.1% | 18.1% | 2nd least demanding of 9 |
| Growth delivered (Del g) | +7.9% | +9.6% | 4th lowest of 9 |
| Hurdle (Req g minus delivered) | +1.2 pp | +13.5 pp | 3rd least demanding of 9 |
| ROIC minus cost of capital | -0.3 pp | -4.1 pp | 4th highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 79.7× | 9.1% | +7.9% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | n/a | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | n/a | 36.3% | +16.2% |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 32.2× | 27.1% | +31.4% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | n/a | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | n/a | n/a | n/a |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | n/a | 25.2% | +10.3% |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | n/a | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 10.2× | -8.7% | +8.8% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 83.1× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | n/a | 10.9% | -5.9% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | n/a | 10.1% | +2.1% |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 112.1× | 31.9% | +19.8% |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 10.1× | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 5.4× | 9.1% | -25.1% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 24.9× | n/a | n/a |